Search results
Results from the WOW.Com Content Network
Xanomeline/trospium chloride, sold under the brand name Cobenfy, is a fixed-dose combination medication used for the treatment of schizophrenia. [1] It contains xanomeline , a muscarinic agonist ; and trospium chloride , a muscarinic antagonist . [ 1 ]
Xanomeline/trospium, sold under the brand name Cobenfy, is an approved combination drug used in the treatment of schizophrenia. [ 6 ] [ 7 ] Trospium chloride is a peripherally selective non-selective muscarinic antagonist to quell peripheral muscarinic agonist-dependent side effects.
William Blair analysts expect $2.5 billion in U.S. sales for Cobenfy by 2030. Bristol said it expects to make the drug available to patients by late October at a list price of $1,850 a month or ...
The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years. Cobenfy, manufactured by Bristol Myers Squibb ...
Health care cost as percent of GDP (total economy of a nation). [2] [3] Graph below is life expectancy versus healthcare spending of rich OECD countries. US average of $10,447 in 2018. [7] See: list of countries by life expectancy.
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
The cost aggregate method must be used if the selling price of a product or service cannot be substantiated. In this method, an IRB contractor aggregates the costs of parts and materials produced in Canada; Canadian transportation costs; Canadian labour costs; Canadian real estate costs; Canadian insurance costs; and several other eligible expenses.
In Canada the total cost of settlements, legal fees, and insurance comes to $4 per person each year, [113] but in the United States it is over $16. Average payouts to American plaintiffs were $265,103, while payouts to Canadian plaintiffs were somewhat higher, averaging $309,417. [ 114 ]